Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 05-14-2024 | 03-31-2024 | 10-Q | |
| 2 | 03-26-2024 | 12-31-2023 | 10-K | |
| 3 | 12-14-2023 | 09-30-2023 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3 and was generally well-tolerated at all doses tested,...
For the first time, the company shares data for its preclinical IL-18 and IL-12 programs—candidate nominations for each are exp...
Morgan Stanley analyst Judah Frommer initiates coverage on Mural Oncology (NASDAQ:MURA) with a Overweight rating and announc...
Mural Oncology (NASDAQ:MURA) reported quarterly losses of $(3.57) per share. This is a 22.68 percent decrease over losses of $(...
Shares of Applied UV, Inc. (NASDAQ: AUVI) shares jumped in pre-market trading after the company reported third-quarter results.
Shares of Dolby Laboratories, Inc. (NYSE: DLB) fell during Friday’s session following weak guidance.
Shares of The Gap, Inc. (NYSE: GPS) jumped in pre-market trading after the company reported better-than-expected financial re...
